公开(公告)号：US20100226803A1

公开(公告)日：2010-09-09

申请号：US12784529

申请日：2010-05-21

Applicant: Fumio TAJIMA ,  Masashi Kitamura ,  Yuji Enomoto ,  Yuji Nomoto ,  Kenya Takarai

Inventor： Fumio TAJIMA ,  Masashi Kitamura ,  Yuji Enomoto ,  Yuji Nomoto ,  Kenya Takarai

IPC: F04D13/06 ,  H02K1/12 ,  H02K1/02 ,  H02K1/04

CPC classification number: F04D13/064 ,  B60L1/003 ,  B60L1/02 ,  B60L3/0061 ,  B60L11/14 ,  B60L2210/40 ,  B60L2240/34 ,  B60L2240/36 ,  B60L2240/425 ,  B60L2270/142 ,  B60L2270/145 ,  F04D13/0633 ,  H02K1/02 ,  H02K1/145 ,  H02K5/12 ,  H02K7/14 ,  H02K21/145 ,  Y02T10/641 ,  Y02T10/642 ,  Y02T10/70 ,  Y02T10/7077 ,  Y02T10/7241

Abstract: A pump is driven by a compact electric motor in which a coil is disposed in a ring form around and along a stator core which has a plurality of claw magnetic poles that extend alternately from both ends of one member of the stator core toward the end of the other member thereof. A stator core can be made from a compressed powder core by molding with resin, with the molded portion able to serve as a partition separating pump and motor units.

公开(公告)号：US06270314B1

公开(公告)日：2001-08-07

申请号：US09397149

申请日：1999-09-16

Applicant: Yuji Nomoto

Inventor： Yuji Nomoto

IPC: F04D2916

CPC classification number: F04D29/426 ,  F04D29/086 ,  F04D29/167

Abstract: A water pump for an internal combustion engine having a pump casing and a pump cover that forms a circulation cavity. A plate is positioned interface of the pump casing and the pump cover and divides the circulation cavity into an inlet passage and an outlet passage and has a seal portion that seals against the leakage between the inlet passage and the outlet passage of a gap of the interface of the pump casing and the pump cover.

Abstract translation: 一种用于内燃机的水泵，其具有形成循环腔的泵壳体和泵盖。 板被定位在泵壳体和泵盖的界面上，并将循环腔分成入口通道和出口通道，并且具有密封部分，该密封部分密封入口通道和出口通道之间的界面间隙的泄漏 的泵壳和泵盖。

公开(公告)号：US4668683A

公开(公告)日：1987-05-26

申请号：US841656

申请日：1986-03-20

Applicant: Haruki Takai ,  Yuji Nomoto ,  Tadashi Hirata ,  Tetsuji Ohno ,  Kazuhiro Kubo

Inventor： Haruki Takai ,  Yuji Nomoto ,  Tadashi Hirata ,  Tetsuji Ohno ,  Kazuhiro Kubo

IPC: A61K31/505 ,  A61P9/04 ,  C07D401/14 ,  C07D487/04 ,  C07D403/14

CPC classification number: C07D401/14 ,  C07D487/04

Abstract: Quinazoline derivatives and their pharmaceutically acceptable acid addition salts having the general formula ##STR1## wherein R.sup.1 and R.sup.2 each represents hydrogen or alkyl;R.sup.3 represents alkyl or substituted alkyl;R.sup.7 and R.sup.8 each represent alkoxy;Z is oxygen or sulfur;m is zero or 1;n is zero or an integer from 1 to 5,exhibit a cardiotonic activity with little tendency to cause tachycardia.

Abstract translation: 喹唑啉衍生物及其药学上可接受的具有通式（I）的酸加成盐，其中R 1和R 2各自代表氢或烷基; R3表示烷基或取代的烷基; R7和R8各自表示烷氧基; Z是氧或硫; m为零或1; n为零或1至5的整数，表现出强心剂活性，几乎不引起心动过速。

公开(公告)号：US08022071B2

公开(公告)日：2011-09-20

申请号：US11959341

申请日：2007-12-18

Applicant: Anjali Pandey ,  Robert M. Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

Inventor： Anjali Pandey ,  Robert M. Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

IPC: A61K31/5377 ,  A61K31/517

CPC classification number: C07D401/12 ,  C07D239/94 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。

公开(公告)号：US20110105486A1

公开(公告)日：2011-05-05

申请号：US12960937

申请日：2010-12-06

Applicant: Takao Nakajima ,  Masamori Sugawara ,  Shin-ichi Uchida ,  Tetsuji Ohno ,  Yuji Nomoto ,  Noriaki Uesaka ,  Yoshisuke Nakasato

Inventor： Takao Nakajima ,  Masamori Sugawara ,  Shin-ichi Uchida ,  Tetsuji Ohno ,  Yuji Nomoto ,  Noriaki Uesaka ,  Yoshisuke Nakasato

IPC: A61K31/541 ,  C07D277/38 ,  C07D417/14 ,  C07D401/14 ,  C07D213/89 ,  C07D413/14 ,  C07D279/12 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61P25/28 ,  A61P25/00 ,  A61P3/10 ,  A61P25/12 ,  A61P25/24

CPC classification number: C07D417/06 ,  A61K31/427 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/542 ,  A61K31/551 ,  A61K31/553 ,  A61K31/695 ,  C07D417/04 ,  C07D417/14 ,  C07D491/048 ,  C07D491/10 ,  C07D498/04 ,  C07D513/04

Abstract: Wherein n is an integer of from 0 to 3; R1A is a 5-membered aromatic heterocyclic group containing at least one oxygen atom; R2A is —COR8 (wherein R8 is aryl); R3A is hydrogen or lower alkyl; and R12 represents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R1A, R2A, R3A and R12 are individually optionally substituted.

Abstract translation: 其中n为0至3的整数; R1A是含有至少一个氧原子的5元芳族杂环基; R2A是-COR8（其中R8是芳基）; R3A是氢或低级烷基; R 12表示环烷基，芳基，芳烷基，脂环族杂环基，芳香族杂环基，脂环族环状烷基或芳香族杂环烷基，R1A，R2A，R3A，R12分别任意取代。

公开(公告)号：US20100256361A1

公开(公告)日：2010-10-07

申请号：US12766986

申请日：2010-04-26

Applicant: Takao Nakajima ,  Masamori Sugawara ,  Shin-ichi Uchida ,  Tetsuji Ohno ,  Yuji Nomoto ,  Noriaki Uesaka ,  Yoshisuke Nakasato

Inventor： Takao Nakajima ,  Masamori Sugawara ,  Shin-ichi Uchida ,  Tetsuji Ohno ,  Yuji Nomoto ,  Noriaki Uesaka ,  Yoshisuke Nakasato

IPC: C07D417/14 ,  C07D413/14 ,  C07D498/04

CPC classification number: C07D417/06 ,  A61K31/427 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/542 ,  A61K31/551 ,  A61K31/553 ,  A61K31/695 ,  C07D417/04 ,  C07D417/14 ,  C07D491/048 ,  C07D491/10 ,  C07D498/04 ,  C07D513/04

Abstract: (Wherein n is an integer of from 0 to 3; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR8, or the like; R3 and R4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR12, or the like)For example, provided are adenosine A2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

Abstract translation: （其中n为0〜3的整数; R 1为取代或未取代的环烷基，取代或未取代的芳基，取代或未取代的脂环族杂环基或取代或未取代的芳香族杂环基; R2为卤素，取代或未取代的低级烷基 取代或未取代的芳基，取代或未取代的脂环族杂环基，取代或未取代的芳族杂环基，-COR 8等; R 3和R 4可以相同或不同，表示氢原子，取代或未取代的低级 烷基，取代或未取代的芳烷基，-COR 12等）例如，提供的是腺苷A 2A受体拮抗剂，其包含作为活性成分的由通式（I）表示的噻唑衍生物或其药学上可接受的盐，以及 类似。

公开(公告)号：US20100113468A1

公开(公告)日：2010-05-06

申请号：US12471280

申请日：2009-05-22

Applicant: Anjali Pandey ,  Robert M. Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

Inventor： Anjali Pandey ,  Robert M. Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

IPC: A61K31/497

CPC classification number: C07D239/94 ,  A61K31/517 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。

公开(公告)号：US20060252780A1

公开(公告)日：2006-11-09

申请号：US10554254

申请日：2004-04-23

Applicant: Takao Nakajima ,  Kimihisa Ueno ,  Yuji Nomoto ,  Yuichi Matsumoto ,  Hiroshi Yano ,  Satoshi Nakanishi ,  Kotaro Takasaki ,  Hideaki Kusaka

Inventor： Takao Nakajima ,  Kimihisa Ueno ,  Yuji Nomoto ,  Yuichi Matsumoto ,  Hiroshi Yano ,  Satoshi Nakanishi ,  Kotaro Takasaki ,  Hideaki Kusaka

IPC: A61K31/519 ,  C07D487/14

CPC classification number: C07D487/14

Abstract: A fused pyrimidine derivative is presented. The derivatie has an insulin secretion stimulating activity represented by Formula (I): {wherein R1 represents a hydrogen atom, lower alkyl, or the like; n represents an integer of 0 to 3; and X1 and X2 may be the same or different and each represents a hydrogen atom, lower alkyl, or the like; and formula (II): represents formula (III): [wherein X—Y—Z represents R2C═CR3—NR4 (wherein R2, R3 and R4 may be the same or different and each represents a hydrogen atom, lower alkyl, or the like)]}, or a pharmaceutically acceptable salt thereof.

Abstract translation: 提出了一种稠合的嘧啶衍生物。 衍生物具有由式（I）表示的胰岛素分泌刺激活性：其中R 1表示氢原子，低级烷基等; n表示0〜3的整数， X 1和X 2可以相同或不同，各自表示氢原子，低级烷基等; 和式（II）：表示式（III）：[其中XYZ表示R 2 C-CR 3 -NR 4（其中R' O 2，R 3和R 4可以相同或不同，各自表示氢原子，低级烷基等）]}， 或其药学上可接受的盐。

公开(公告)号：US20060063770A1

公开(公告)日：2006-03-23

申请号：US11200456

申请日：2005-08-08

Applicant: Anjali Pandey ,  Robert Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

Inventor： Anjali Pandey ,  Robert Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

IPC: A61K31/517

CPC classification number: C07D401/12 ,  C07D239/94 ,  C07D403/12

Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。

公开(公告)号：US20050288297A1

公开(公告)日：2005-12-29

申请号：US11210028

申请日：2005-08-22

Applicant: Anjali Pandey ,  Robert Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

Inventor： Anjali Pandey ,  Robert Scarborough ,  Kenji Matsuno ,  Michio Ichimura ,  Yuji Nomoto ,  Shinichi Ide ,  Eiji Tsukuda ,  Junko Sasaki ,  Shoji Oda

IPC: A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61P9/08 ,  A61P9/10 ,  A61P13/12 ,  A61P35/00 ,  A61P43/00 ,  C07D239/94 ,  C07D401/12 ,  C07D403/12

CPC classification number: C07D239/94 ,  A61K31/517 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Abstract translation: 本发明涉及对抑制这种激酶活性的激酶磷酸化具有抑制活性的含氮杂环化合物及其药学上可接受的盐。 本发明还涉及通过抑制激酶的磷酸化来抑制哺乳动物的激酶和治疗疾病状态的方法。 在一个特定方面，本发明提供了抑制PDGF受体的磷酸化以阻止异常细胞生长和细胞游动的含氮杂环化合物及其药学上可接受的盐，以及预防或治疗细胞增殖性疾病如动脉硬化，血管 重建，癌症和肾小球硬化症。